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CONTEXT: Although office-based opioid treatment with
buprenorphine (OBOT-B) has been successfully imple-
mented in primary care settings in the US, its use has
not been reported in homeless patients.
OBJECTIVE: To characterize the feasibility of OBOT-B
in homeless relative to housed patients.
DESIGN: A retrospective record review examining treat-
ment failure, drug use, utilization of substance abuse
treatment services, and intensity of clinical support by
a nurse care manager (NCM) among homeless and
housed patients in an OBOT-B program between Au-
gust 2003 and October 2004. Treatment failure was
defined as elopement before completing medication
induction, discharge after medication induction due to
ongoing drug use with concurrent nonadherence with
intensified treatment, or discharge due to disruptive
behavior.
RESULTS: Of 44 homeless and 41 housed patients
enrolled over 12 months, homeless patients were more
likely to be older, nonwhite, unemployed, infected with
HIV and hepatitis C, and report a psychiatric illness.
Homeless patients had fewer social supports and more
chronic substance abuse histories with a 3- to 6-fold
greater number of years of drug use, number of
detoxification attempts and percentage with a history
of methadone maintenance treatment. The proportion
of subjects with treatment failure for the homeless
(21%) and housed (22%) did not differ (P=.94). At
12 months, both groups had similar proportions with
illicit opioid use [Odds ratio (OR), 0.9 (95% CI, 0.5–1.7)
P=.8], utilization of counseling (homeless, 46%; housed,
49%; P=.95), and participation in mutual-help groups
(homeless, 25%; housed, 29%; P=.96). At 12 months,
36% of the homeless group was no longer homeless.
During the first month of treatment, homeless patients
required more clinical support from the NCM than
housed patients.
CONCLUSIONS: Despite homeless opioid dependent
patients’ social instability, greater comorbidities, and
more chronic drug use, office-based opioid treatment
with buprenorphine was effectively implemented in this
population comparable to outcomes in housed patients
with respect to treatment failure, illicit opioid use, and
utilization of substance abuse treatment.
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INTRODUCTION
Opioid abuse persists as a pervasive public health problem in
the United States, both heroin1 and prescription opioid
analgesics.1,2 Opioid agonist treatment with methadone or
buprenorphine is effective for treating opioid dependence.3–12
With the advent of sublingual buprenorphine for the treatment
of opioid dependence, primary care physicians in the United
States gained the opportunity to effectively treat opioid-
dependent patients in primary medical care settings, common-
ly referred to as office-based opioid treatment (OBOT).13,14
In 2003, the primary care clinic at Boston Medical Center
(BMC) implemented an OBOT with buprenorphine (OBOT-B)
program employing collaborative care between physicians and
a nurse care manager (NCM).15 All patients in the BMC pri-
mary care clinic OBOT-B program were required to have stable
housing, as clinical guidelines recommend a stable social
environment as an entry criterion for OBOT-B.16,17 Using social
stability as a criterion for OBOT-B precludes homeless persons,
a population with a high prevalence of addiction,18–21 leading to
a high risk of illness and death.22–25
Unique challenges confront homeless individuals engaging
in substance abuse treatment,26 which likely contribute to
their high rates of treatment failure.27,28 Characteristics of
homeless persons are correlated with relapse: lack of social
support; unstable living environment; and longer duration of
drug dependence.29,30 However, research has shown that
homeless persons’ success in substance abuse treatment can
increase under supportive circumstances.30,31 Furthermore,
despite limited literature on methadone treatment in homeless
populations, published data suggest greater success with
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enhanced access to32 and unconventional methods of treat-
ment (e.g., medical care provision in homeless health care
settings).33 Although homeless opioid dependent individuals
may benefit from buprenorphine treatment, clinical guidelines
have excluded them.
This retrospective cohort study characterizes the feasibility of
office-based opioid treatment with buprenorphine (OBOT-B) in
a homeless population. We describe a customized model of OBOT-
B care and outcomes in homeless compared to housed patients.
METHODS
Program Description
Model of Care. In August 2003, OBOT-B was implemented in
an urban academic medical center for homeless patients in a
homeless clinic and for housed patients in a primary care
clinic. Both patient groups were treated with collaborative care
between qualified primary care physicians (PCPs) and a single
nurse care manager (NCM). All patients were referred by their
respective clinics and were to receive maintenance buprenor-
phine treatment for at least 12 months. Homelessness was
defined as spending 1 or more weeks on the street or in a shelter
within the previous 3months.Upon referral by the PCP, homeless
and housed patients were admitted successively or placed on a
wait list when the practice was at capacity due to the federally
mandated 30-patient-per-practice limit at the time of the study.
Our model of care included 4 stages of treatment: (1) Determina-
tion of eligibility; (2) Medication induction; (3) Medication stabi-
lization; (4) Treatment maintenance.
Determination of Eligibility. Assessment protocols were similar
for homeless and housed groups. OBOT-B, a less structured
treatment option compared to methadone maintenance
treatment, required a patient assessment for appropriateness.
OBOT-B appropriateness was determined by adherence with
assessment appointments, mental health stability [i.e., ability
to comprehend and consent to OBOT-B protocols, chronic
mental illness with ongoing psychiatric care and no acute
mental health issues (e.g., suicidal ideation)], absence of
painful conditions requiring opioid analgesics, absence of
medical contraindications (e.g., pregnancy or liver function
tests greater than five times the normal level), and absence of
alcohol or other drug co-dependence. Patients with sporadic
alcohol or other drug use remained eligible. Patients on
methadone maintenance doses greater than 30 mg per day
were excluded based on current practice guidelines.16 If deemed
appropriate for OBOT-B, patients received a comprehensive
assessment by the NCM that included a detailed medical,
psychiatric, and substance abuse history including documen-
tation of DSM-IV diagnosis of opioid dependence. Social history
included employment and homelessness status. Admission lab
work included a complete blood count, electrolytes, renal and
liver function tests, hepatitis A, B, and C serologies, and urine
toxicology for opioids (including oxycodone for patients with a
history of oxycodone abuse), cocaine, benzodiazepines, barbi-
turates, and amphetamines. All patients were tested for tuber-
culosis exposure and were offered HIV testing and counseling.
Treatment consents and individualized treatment plans were
reviewed and signed by both patient and NCM. At a separate
appointment, PCPs reviewed the NCM assessment and treat-
ment plan, performed a complete physical examination, and
wrote the initial buprenorphine prescription. Patients were
strongly encouraged to utilize other substance abuse services,
including addiction counseling and mutual-help groups [e.g.,
Narcotics Anonymous (NA)].
Medication Induction. Induction, occurring during the first
3 days of treatment, differed for homeless and housed patients.
Homeless patients received “office induction,” with up to
8 hours observation on day 1 by the NCM for the following:
signs of opioid withdrawal, dose administration, and response
to medication. Homeless patients left the office with a night-
time dosing protocol to be used if withdrawal recurred and
then returned daily for the next 2 days for dose adjustments.
In contrast, because all housed patients were reachable by
telephone, they received “home induction” by following a 3-day
dosing protocol at home. The 3-day protocol gave specific
dosing schedules with a maximum daily dose for each day (i.e.,
max dose, 8, 16, and 24 mg for days 1, 2, and 3, respectively).
The NCM called all housed patients at home before the first
buprenorphine dose was taken and then at least daily during
the 3-day induction. The NCM was available during business
hours for drop-in visits and 24 hours a day via cell phone.
Medication Stabilization. Stabilization, occurring during days 4
through 14 of treatment, differed for homeless and housed
patients. Homeless patients presented to the clinic daily,
except weekends, for observed dosing and assessment while
housed patients were seen twice per week but had at least
daily NCM phone contact.
Treatment Maintenance. Ongoing monitoring for drug use and
treatment adherence, occurring beyond day 14 of treatment,
was based on individual patient needs in both groups. Bupre-
norphine prescriptions were provided in 1 to 4 week amounts
determined by the patient’s ability to safely secure medica-
tions. For example, 1-week amounts for patients without a
secure storage place and 2–4 week amounts for patients with a
secure storage place. Patients were seen at least monthly by
the NCM and at least every 6 months by the PCP. Patients were
expected to respond to unscheduled “call-backs” to the clinic
for urine toxicology, observed dosing, pill counts, and revisions
of treatment plans as needed. The need for “call-backs” was
based on the NCM or PCP’s clinical suspicion that the patient
may have relapsed or may be diverting their medication based
on abnormal urine toxicology, reports of lost pills, requests for
early refills, or missed appointments. Urine was tested for
opioids (including oxycodone for patients with a history of
oxycodone abuse) and other drugs (including cocaine, benzo-
diazepines, barbiturates, and amphetamines) as well as bupre-
norphine at least every 3 months. Intensified treatment (i.e.,
substance abuse counseling) was required for patients with
ongoing use of opioids, other drugs, or alcohol.
Patient Characteristics
Upon entry into OBOT-B, patients’ demographics, employ-
ment, homelessness status, involvement of socially supportive
individuals, opioid, other drug and alcohol use, and substance
abuse, medical and psychiatric histories were recorded.
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Outcome Assessments
Time to Treatment Failure. Our primary outcome was time to
“treatment failure” defined as any of the following: elopement
before completing medication induction (elopement did not
occur after induction); discharge after medication induction
due to ongoing use of opioids, other drugs or alcohol with
concurrent nonadherence with intensified substance abuse
treatment; or discharge due to disruptive behavior (e.g.,
threatening staff, theft of clinic property).
Secondary outcomes included reasons for leaving the
OBOT-B program (including treatment failure and successful
program departures), illicit opioid and other drug use, number
of NCM contacts, utilization of recommended care and social
indicators (e.g., homelessness and employment status).
Reasons for Leaving the OBOT-B Program. All patients who left
the program before 12 months were categorized into one of the
following 2 groups: “treatment failure” (defined above); or
“successful program departure.” Patients classified as
“successful program departure” left the program because
they relocated and were transferred to another OBOT
program, they needed a more structured treatment setting
and were transferred to a methadone maintenance program, or
they were fully adherent with treatment for at least 4 months
and were approved for a medication taper by both the NCM
and PCP.
Illicit Drug Use. Both planned and “call-back” urine toxicology
were conducted at least once every 3 months. In each
assessment window (i.e., at entry, 3, 6, 9, and 12 months of
treatment), the test that was closest, yet prior, to the timepoint
was reported, in an attempt to obtain a measure of abstinence
that was not biased by the number of urine toxicology tests
performed. Urine toxicology tests were mostly unsupervised
but measures were taken to try to minimize falsified tests (e.g.,
testing for buprenorphine metabolites, urine temperature, and
creatinine concentration). Urine collections were supervised
when the NCM suspected falsified tests due to the following
circumstances: patient had a recent history of abnormal urine
tests; specimens were cold or diluted; patient demonstrated
aberrant behavior (e.g., missed clinic appointments, requested
early medication refill). The following 3 outcomes were
determined by record review: number of NCM contacts (phone
calls and clinic visits during each month of treatment);
utilization of recommended care (involvement in substance
abuse counseling and/or mutual-help groups defined by at
least weekly attendance for 1 or more months before record
review); and social indicators [homelessness, employment
status (self-reported employment for at least 1 month) and
presence of social supports (family member or friend actively
involved in the patient’s substance abuse rehabilitative progress
and in contact with the NCM within the previous 3 months)].
For all patients who left the OBOT-B program (treatment
failure and successful program departure), follow-up data
post-departure were not collected.
Analysis
Descriptive statistics (e.g., means and proportions) were used
to characterize homeless and housed groups. Exploratory,
hypothesis-generating tests were then performed to compare
process and outcome measures between groups. Chi-square or
Fisher’s exact tests were used to compare dichotomous out-
comes and t-tests or Wilcoxon rank sum tests were used to
compare continuous outcomes between groups. NCM contacts
were described for each group using the mean number of
contacts per patient for each month of follow-up. Poisson
regression models were constructed to estimate the rate ratio
of NCM contacts in the homeless relative to housed groups.
Generalized estimating equations (GEE) regression models
were used to examine the association between homelessness
status and drug use. Data collected from entry, 3, 6, 9, and 12-
month timepoints were analyzed. The proportions of treatment
failures were estimated using the Kaplan–Meier method and
compared between groups using the log-rank test. Successful
program departures were censored at their date of departure,
as follow-up data were not available beyond that date.
Reported P-values are two-tailed, and a P-value of less than
.05 was considered statistically significant. All analyses were
run using SAS statistical software.34 This research was
approved by the Institutional Review Board at Boston Univer-
sity Medical Center.
RESULTS
Patient Characteristics
During the 12 months examined, 44 homeless and 41 housed
patients were enrolled. The homeless group had fewer males,
fewer whites, were older, and less employed compared to the
Table 1. Comparison of Homeless and Housed Patients at Time of
Entry into Office-Based Opioid Treatment with Buprenorphine
Homeless
(N=44)
Housed
(N=41)
P-value
Demographics
Male (%) 59 76 .11
Race/ethnicity <.001
White (%) 41 85
Hispanic/Latino (%) 34 2
Black/African American (%) 25 12
Mean age years (SD) 42 (9.1) 34 (10.4) <.001
Employed (%) 5 34 <.001
Involvement of social
support in care (%)
2 90 <.001
Comorbidity
Self-reported psychiatric
illness (%)
95 54 <.001
HIV-infected (%) 30 5 .003
Hepatitis C-infected (%) 95 44 <.001
Substance abuse history
Opioid at admission .001
Heroin (%) 84 63
Sustained-release
oxycodone (%)
0 27
Methadone
maintenance (%)
16 10
Any methadone
maintenance history (%)
59 10 <.001
Median years drug
use (range)
15 (5–30) 5 (2–12) <.001
Median detoxification
attempts (range)
18 (5–40) 5 (0–20) <.001
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housed group. There was a dramatic difference in social
supports, essentially nonexistent for the homeless patients
but present for almost all housed patients. Similarly, comor-
bidities were clearly different in the homeless versus the
housed group with 95% reporting psychiatric illness versus
54%, 30% HIV-infected versus 5%, and 95% hepatitis C
infected versus 44%, respectively. At time of study entry, 84%
of the homeless patients were dependent on heroin with none
dependent on oxycodone versus 63% heroin dependent and
27% oxycodone dependent in the housed patients. The
remaining 16% of the homeless and 10% of housed patients
were transferred from methadone maintenance treatment.
Homeless patients also had more chronic substance abuse
histories with a 3- to 6-fold greater number of years of drug
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Figure 1. Kaplan–Meier estimates of the proportion of homeless
and housed patients who did not fail office-based opioid treatment
with buprenorphine. P=.94 for the comparison between homeless
and housed subjects by the log-rank test.
Table 2. Reasons for Leaving Office-Based Opioid Treatment with
Buprenorphine Among Homeless (n=20*) and Housed (n=17*)
Patients
Homeless
N (%)
Housed
N (%)
Treatment failure
Elopement during induction†† 3 (15) 3 (18)
Ongoing drug use and treatment
nonadherence§
3 (15) 5 (29)
Disruptive behavior// 2 (10) 0 (0)
Successful program departures
Transfer to another OBOT-B program 1 (5) 0 (0)
Transfer to methadone maintenance
program
5 (25) 4 (24)
Successful taper¶ 6 (30) 5 (29)
*Of the 44 homeless and 41 housed subjects who entered the study, 20
homeless and 17 housed subjects did not remain in the program for
12 months.
††No elopement occurred after induction period.
§Ongoing use of opioids or other drugs with concurrent nonadherence of
intensified treatment.
//Including threatening staff and theft of clinic property.
¶Treatment adherence including no drug use for at least 4 months,
followed by successful tapering off of the program.
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Figure 2. Mean number of monthly nurse care manager (NCM)
contacts per homeless and housed patient over 12 months of
office-based opioid treatment with buprenorphine. *RR=1.7 (95%
CI=1.48–1.95); P<.0001 (homeless vs housed in month #1).
Table 3. Outcomes of Homeless (N=44) and Housed (N=41)
Patients after 12-months of Office-Based Opioid Treatment with
Buprenorphine
Homeless
N (%)
Housed
N (%)
P-value
Attending counseling† 0.95
Yes 20 (46) 20 (49)
No 4 (9) 4 (10)
Unknown 20 (46) 17 (42)
Attending mutual help
groups†
0.96
Yes 11 (25) 12 (29)
No 13 (30) 12 (29)
Unknown 20 (46) 17 (42)
Currently homeless†† 0.03
Yes 8 (18) 1 (2)
No 16 (36) 23 (56)
Unknown 20 (46) 17 (42)
Currently employed§ 0.07
Yes 17 (39) 23 (56)
No 7 (16) 1 (2)
Unknown 20 (46) 17 (42)
Involvement of social
support in care//
0.50
Yes 22 (50) 24 (59)
No 2 (5) 0 (0)
Unknown 20 (46) 17 (42)
†Weekly attendance for 1 or more months.
††Spending 1 or more weeks on the street or in a shelter within the
previous 3 months.
§Maintaining employment for 1 or more months.
//Family member or friend actively involved in the patient’s substance
abuse rehabilitative progress and in contact with the NCM within the
previous 3 months.
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use, number of detoxification attempts, and percentage with a
history of methadone maintenance treatment (Table 1).
Patient Outcomes
The estimated proportion of subjects with treatment failure
was 21% for the homeless and 22% for the housed. Homeless
and housed patients did not differ in their risk for treatment
failure during follow-up (P=.94) (Fig. 1).
Mean duration of OBOT-B retention was 9 months for both
homeless and housed groups. The percentage of patients
remaining in OBOT-B (i.e., had not failed, transferred or
tapered) at the 3-, 6-, 9- and 12-month timepoints was 77%,
73%, 70%, and 55% in the homeless group and 93%, 80%,
68%, and 61% in the housed group. The number of patients
who left treatment and the reasons for leaving treatment before
12-months, including the treatment failure and successful
program departure groups, appeared similar for both groups
(Table 2).
Of the patients remaining in treatment at 3 months, urine
samples were positive for illicit opioids in 11% of homeless and
20% of housed patients and at 12 months positive in only 4%
in both groups. At entry, urines were positive for “other drugs”
in 34% of homeless and 32% of housed patients and of those
remaining in treatment at 12 months, positive in only 8% in
both groups. Over the 12-month period, no significant asso-
ciations were found between homelessness status and use of
opioids [Odds ratio (OR) 0.9 (95% CI, 0.5–1.7); P=.8] or other
drugs [OR 1.7 (95% CI, 0.7–4.3); P=.2).
The mean number of NCM contacts per patient was
estimated by homelessness status for each month of follow-
up (Fig. 2). During the first month of treatment (induction and
stabilization), the rate of NCM contacts per patient in the
homeless group was 1.7 times that in the housed group (95%
CI=1.48–1.95; P<.0001). At 12 months, 46% of homeless and
49% of housed patients reported at least weekly receipt of
substance abuse counseling and 25% of homeless and 29% of
housed patients reported at least weekly mutual-help group
attendance (Table 3). At 12 months, of the 44 homeless
patients originally enrolled, 16 (36%) no longer met the criteria
for homelessness. Employment increased for both homeless
and housed patients that remained in the program for
12 months.
DISCUSSION
Office-based opioid treatment with buprenorphine (OBOT-B)
was effectively implemented in homeless patients with out-
comes comparable to housed patients. When compared to
housed patients, homeless patients appeared to have a similar
proportion of treatment successes (i.e., retention in treatment,
successful program departure, decreased drug use, and
utilization of counseling and mutual help groups), despite
having more chronic substance abuse histories (e.g., greater
number of years of drug use, detoxification attempts, and
history of methadone maintenance treatment), more medical
and psychiatric comorbidities, and less social support. Em-
ployment and housing increased substantially among home-
less patients. Homeless patients required more clinical
support by the Nurse Care Manager (NCM) than housed
patients during the first month of treatment. However, not-
withstanding the increased support required, feasibility of
OBOT-B care to homeless patients was demonstrated and
outcomes appeared comparable to a housed group.
These findings conflict with previous reports of poorer
addiction treatment outcomes in homeless populations,27,28,32
but are consistent with studies in which homeless-specific
interventions improved addiction outcomes. Milby et al. ran-
domized 176 homeless substance abusers to either usual or
enhanced care. Enhanced care entailed daily psychoeduca-
tional groups and weekly individual counseling, plus absti-
nence-contingent employment and housing starting at
month 4 of treatment. Subjects receiving enhanced care had
significantly lower rates of alcohol and drug use during the
12 months of follow-up.31 Kertesz et al. found an association
between post-detoxification stabilization programs and time to
substance use post-discharge from a residential detoxification
program for homeless persons with addictions.30
This study provides further evidence that addiction treat-
ment in homeless populations can yield effective results. It
suggests that more than the usual resources, such as
availability of a NCM, may be required for this population
when pursuing substance abuse treatment.
The availability of a NCM also allowed us to implement a
home-based medication induction protocol, which is not
currently recommended by national guidelines, through daily
phone contact between the NCM and housed patients.
Several limitations to this study should be considered.
While data were collected prospectively during clinical care
using a carefully designed medical record, the study was
retrospective. In addition, follow-up data were not available
once patients departed the program. However, of patients who
left the program earlier than 12 months, the reasons for
leaving (i.e., treatment failure vs successful program depar-
ture) appeared similar between homeless and housed groups.
To assess the value of an OBOT-B program in homeless
persons, one ideally would compare outcomes with homeless
persons requesting substance abuse treatment who did not get
access to buprenorphine. However, this study was not
intended to retest the efficacy of buprenorphine treatment,
but rather, evaluate the feasibility of delivering this known
effective treatment in a homeless population. Thus, the
comparison group in this study was non-homeless persons
receiving buprenorphine. An experienced, skilled NCM played
an essential role in caring for patients in the programs
described. Generalizability of such a model may depend on
skills of such a key individual. Generalizability may also
depend on the level of collaboration among practitioners within
the microsystem in which the care is delivered.35 The provider
collaboration component of the OBOT-B program was not
explicitly measured in this study. Finally, although the total
number of patients in this study is small, a consequence of the
federal law limiting the number of patients receiving bupre-
norphine in a single clinical practice, the findings are robust
and statistically significant.
In conclusion, office-based opioid treatment with buprenor-
phine (OBOT-B) can be effective in homeless patients. In this
study, despite homeless patients’ greater comorbidities, less
social support, and more chronic substance use histories,
their outcomes in terms of treatment failure and illicit drug use
were comparable to housed patients. Social benefits, specifi-
cally gaining access to housing and employment, occurred in a
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surprisingly high percentage of the homeless OBOT-B patients.
Beyond individual clinical benefit, potentially unmeasured
public health benefits regarding risk behaviors and health
care utilization need to be further assessed. Using appropriate
models of care, buprenorphine treatment for opioid depen-
dence among homeless persons should be implemented.
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